Lee P. Richman

发表

Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma

D. Torigian, E. Wherry, J. Melenhorst, 2018, Oncoimmunology.

Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking

R. Vonderheide, Lee P. Richman, 2014, Oncoimmunology.

Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer

R. Vonderheide, Lee P. Richman, 2013, Cancer Immunology Research.

Priority Brief Role of Crosslinking for Agonistic CD 40 Monoclonal Antibodies as Immune Therapy of Cancer

R. Vonderheide, Lee P. Richman, 2013 .

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis

S. Friedman, G. Moyle, H. Yoneyama, 2016, PloS one.

Tumor Cell‐Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy

S. Lowe, J. Tobias, L. Coussens, 2018, Immunity.

Neoantigen Dissimilarity to the Self-Proteome Predicts Immunogenicity and Response to Immune Checkpoint Blockade.

R. Vonderheide, A. Rech, Lee P. Richman, 2019, Cell systems.

Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment

D. Porter, B. Levine, C. June, 2016, American journal of hematology.

High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning.

D. Porter, R. Mick, T. Kambayashi, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Toll‐like receptor 9 and interferon‐γ receptor signaling suppress the B‐cell fate of uncommitted progenitors in mice

E. Behrens, Lee P. Richman, N. Chu, 2015, European journal of immunology.

Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting

B. Garcia, G. Linette, D. Powell, 2021, Nature Communications.

Vitamin D deficiency after allogeneic hematopoietic cell transplantation promotes T-cell activation and is inversely associated with an EZH2-ID3 signature.

D. Porter, C. Pasin, A. Yates, 2021, Transplantation and cellular therapy.

CCR5-edited CD4 T cells augment HIV-specific immunity to enable post rebound control of HIV replication.

D. Porter, B. Levine, C. June, 2021, The Journal of clinical investigation.

Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis.

J. Hoxie, D. Porter, R. H. Moy, 2017, Blood.

Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression.

T. Flotte, B. Trapnell, James M. Wilson, 2013, The Journal of clinical investigation.

Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2).

J. Tobias, G. FitzGerald, B. Stanger, 2019, The Journal of clinical investigation.

NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT.

T. Kambayashi, A. Fesnak, D. Raulet, 2015, Blood.

TRANSPLANTATION NKG 2 D expression by CD 8 1 T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT

T. Kambayashi, A. Fesnak, D. Raulet, 2015 .

Miniatures Immune Activation and a 9-Year Ongoing Complete Remission Following CD 40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma

C. Desmarais, D. Torigian, K. Nathanson, 2014 .

Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma

C. Desmarais, D. Torigian, K. Nathanson, 2014, Cancer Immunology Research.

Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis.

D. Porter, R. Vonderheide, R. Reshef, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Extended Course of Maraviroc, a CCR5 Antagonist, Is Safe and Effective in Graft-Versus-Host Disease Prophylaxis. Final Results of a Phase II Study

J. Hoxie, D. Porter, E. Acosta, 2017 .

Abstract CT137: Combination of agonistic CD40 monoclonal antibody CP-870,893 and anti-CTLA-4 antibody tremelimumab in patients with metastatic melanoma

D. Torigian, E. Wherry, M. Riese, 2015 .

Abstract B04: Identification of T-cell receptors targeting mutant KRAS in pancreatic cancer

G. Linette, M. O'Hara, B. Carreno, 2019 .

Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression.

T. Flotte, B. Trapnell, James M. Wilson, 2013, The Journal of clinical investigation.

NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT.

T. Kambayashi, A. Fesnak, D. Raulet, 2015, Blood.

Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis.

J. Hoxie, D. Porter, R. H. Moy, 2017, Blood.

High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning.

D. Porter, R. Mick, T. Kambayashi, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Toll‐like receptor 9 and interferon‐γ receptor signaling suppress the B‐cell fate of uncommitted progenitors in mice

E. Behrens, Lee P. Richman, N. Chu, 2015, European journal of immunology.

Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma

C. Desmarais, D. Torigian, K. Nathanson, 2014, Cancer Immunology Research.